Calls
1
Jo Yi-jin
Private Banker
Win Rate
0.0%
return
-3.8%
Loading charts...
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jun 11
$407500.00
-3.8%
Hanmi Pharm's stock has corrected to historical valuation lows while the company is poised for multiple near-term catalysts: a domestic obesity drug launch in Q4, a muscle-preserving obesity treatment in phase 3, a recent landmark $1.9 trillion KRW licensing deal with only a 6% up-front refundable payment, and potential further deals. The bio sector is deeply oversold and a single positive catalyst could reverse the entire selloff.
Pharma & Biotech
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Jo Yi-jin has 1 trade ideas tracked on Buzzberg across 1 tickers since June 2026. Most covered: 128940.KS.
